Announcement • Sep 07

Aroa Biosurgery Limited Reports Interim Results from Ongoing Mastrr Registry Evaluating Myriad Matrix and Myriad Morcells in Complex Soft Tissue Reconstruction

Aroa Biosurgery Limited announced the peer-reviewed publication of interim results from its ongoing MASTRR Registry, reporting low infection rates and no adverse events definitely related to Myriad products. Published in Advances in Therapy, the interim analysis included 411 patients and 474 soft tissue defects treated across 10 US centers. Myriad Matrix and Myriad Morcells were evaluated across a broad range of complex soft tissue reconstruction procedures in a highly challenging real-world patient population. Approximately 59% of patients were ASA Class III or IV, indicating significant underlying systemic disease. In addition, 35% had diabetes, 30% had vascular disease and 23% used nicotine. The defects were similarly complex, with approximately 89% clean-contaminated or contaminated, 59% chronic, 15% involving confirmed osteomyelitis and 11% involving exposed structures, including bone, tendon or viscera. Despite this complexity, deep tissue infection occurred in only 0.7% of patients and superficial infection in 2.9%. No infections were attributed to Myriad over a median follow-up period of 27 weeks. Across the 474 defects, the median number of Myriad applications was one. The authors of the interim analysis discussed Myriad's low infection rates in the context of infection rates reported for several resorbable synthetic bioscaffold products used in complex soft tissue reconstruction, as reported in separately published meta-analyses. Those reported infection rates ranged from 16% to 25%. Post-operative infections can delay healing, increase the risk of further complications and may require additional treatments, surgical interventions or hospitalization. A large US analysis of patients undergoing open surgical procedures found that a surgical site infection added an average 7.8–9.3 days to a patient's hospital stay and approximately USD 18,600–USD 21,000 in healthcare costs, with deep tissue infections creating an even greater burden. While the MASTRR interim analysis assessed safety rather than healthcare utilization or cost savings, Aroa said Myriad's favourable infection profile may be relevant to healthcare providers managing complex soft tissue defects. The MASTRR Registry is an ongoing prospective, multicenter observational study evaluating the real-world safety and performance of Myriad Matrix and Myriad Morcells. More than 550 patients are currently enrolled, and the registry is approved to enroll up to 800 patients across 15 US sites. The publication adds to previously published procedure-specific analyses from the MASTRR Registry in lower extremity reconstruction, trauma, burns, pilonidal disease and pressure injuries. Aroa expects the expanding registry dataset to support further analyses across multiple surgical specialties and applications. Aroa said the findings support the growing body of clinical evidence for Myriad and build on the product's strong commercial momentum, following 54% sales growth in Fiscal year 2026. The study, Safety of Ovine Forestomach Matrix Across 474 Soft Tissue Defects: Interim Results from the Prospective Multicenter MASTRR Registry, has been published in Advances in Therapy and is available online.

Aroa Biosurgery Limited Stock Price

ARX Share Price Performance

ARX Community Narratives

Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier

CMS Reforms And International Expansion Will Drive US Healthcare Adoption

Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time

Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier

CMS Reforms And International Expansion Will Drive US Healthcare Adoption

Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time

Trending Discussion

Recently Updated Narratives

ARX: Higher Multiple And Earnings Outlook Will Support Future Upside

ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power

Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time

Snowflake Analysis

Aroa Biosurgery Limited Key Details

About ARX

Recent ARX News & Updates

Aroa Biosurgery Limited Reports Interim Results from Ongoing Mastrr Registry Evaluating Myriad Matrix and Myriad Morcells in Complex Soft Tissue Reconstruction

Aroa Biosurgery Limited Appoints Michael Lynskey as Chief Commercial Officer and A Member of the Executive Leadership Team

Aroa Biosurgery Limited Announces Resignation of James Agnew from Chief Financial Officer, Effective from End of November 2026

Recent updates

Aroa Biosurgery Limited Competitors

Racura Oncology

Clinuvel Pharmaceuticals

Tetratherix

Starpharma Holdings